Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.31 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26433461 | 0.95 | ALOX5 (0.36) | ALOX5PLA2G2APLA2G4A | |
| SCHEMBL26433437 | 0.95 | KDM4E (0.33) | ALOX5KDM4EALDH1A1GAAMAPT | |
| SCHEMBL25021002 | 0.92 | ALOX5 (0.40) | ALOX5PLA2G2APLA2G4A | |
| SCHEMBL26433441 | 0.90 | ALOX5 (0.33) | ALOX5KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL25021238 | 0.90 | ALOX5 (0.38) | ALOX5PLA2G2APLA2G4AKDM4EALDH1A1 | |
| SCHEMBL25020340 | 0.90 | ALOX5 (0.32) | ALOX5 | |
| SCHEMBL26432403 | 0.90 | PLA2G2A (0.34) | ALOX5PLA2G2APLA2G4AMAPTHPGD | |
| SCHEMBL26432570 | 0.90 | PLA2G2A (0.34) | ALOX5PLA2G2APLA2G4AMAPTHPGD | |
| SCHEMBL26433593 | 0.89 | ALOX5 (0.36) | ALOX5 | |
| SCHEMBL26432404 | 0.88 | PLA2G2A (0.34) | ALOX5PLA2G2APLA2G4AMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131749-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20230131749-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2023-04-27 | — | — | US | disclosed |
| EP-4134370-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT Materials Co., Ltd. (KR) | 2023-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131749-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, CYP1A1, CYP1B1 | ALOX5 611/4885PLA2G2A 4255/4885PLA2G4A 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.